Alnylam presents positive preliminary data for ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ: ALNY) has presented positive preliminary results at a medical conference in Japan from its Phase 1 clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis  (ATTR). Data from the study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels [...]

Tekmira plans NASDAQ listing

Tekmira Pharmaceuticals (TSX:TKM) plans to apply to list its common shares on the Nasdaq stock market in the next few months. “Many of our peers have securities listed in the U.S. and we believe doing so is a logical step in the evolution of Tekmira to be appropriately valued as a leader in the RNA [...]